Skip to main content

Gilead Sciences

2022 Breast Cancer Guide to Patient Support Services

Gilead Sciences Support Services

Trodelvy Access Support
Zydelig AccessConnect

Gilead Sciences provides patient support programs that offer help to your patients taking Trodelvy. Trodelvy Access Support provides information about coverage, prior authorization, claims status, and assistance options (Table).

Trodelvy Access Support

Trodelvy Savings Program

The Trodelvy Savings Program provides savings on out-of-pocket expenses for Trodelvy for commercially or privately insured patients. Patients pay $0 out of pocket for Trodelvy, which includes copay and coinsurance up to $25,000 annually. Terms and conditions apply.

  • The program assists with cost of Trodelvy only; patient is responsible for costs of office visits and treatment expenses
  • This program does not support any claims covered, paid, or reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs.

Coverage, coding, billing, and reimbursement requirements for Trodelvy may vary by plan and patient. For additional information about any support issues, contact Trodelvy Access Support at 844-876-3358, option 4.

Gilead Patient Assistance Program

Patients who are uninsured or underinsured may be eligible to obtain access to Trodelvy at no cost through the Gilead Patient Assistance Program. To qualify for assistance, patients must send a completed Enrollment Form via mail or fax. Patients must be legal residents of the United States and meet income requirements and certain additional eligibility criteria.

Third-Party Assistance Referrals

Trodelvy Access Support Case Managers can provide patients who are unable to afford their medication (including those with Medicare, Medicaid, or other government-sponsored insurance) with information about independent third-party organizations that may be able to help with the cost of treatment.

TABLE Gilead Sciences Breast Cancer Drug

Patient support programs

Trodelvy (sacituzumab govitecan-hziy)
Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received ≥2 prior systemic therapies, at least 1 of them for metastatic disease
Patient support programs